Clapham H. auteur aut IRD Hay J. auteur aut IRD Routledge I. auteur aut IRD Takahashi S. auteur aut IRD Choisy Marc auteur aut IRD Cummings D. auteur aut IRD Grenfell B. auteur aut IRD Metcalf C.J.E. auteur aut IRD Mina M. auteur aut IRD Rodriguez-Barraquer I. auteur aut IRD Salje H. auteur aut IRD Tam C.C. auteur aut IRD text journalArticle eng text/pdf reformatted digital access Serologic studies are crucial for clarifying dynamics of the coronavirus disease pandemic. Past work on serologic studies (e.g., during influenza pandemics) has made relevant contributions, but specific conditions of the current situation require adaptation. Although detection of antibodies to measure exposure, immunity, or both seems straightforward conceptually, numerous challenges exist in terms of sample collection, what the presence of antibodies actually means, and appropriate analysis and interpretation to account for test accuracy and sampling biases. Successful deployment of serologic studies depends on type and performance of serologic tests, population studied, use of adequate study designs, and appropriate analysis and interpretation of data. We highlight key questions that serologic studies can help answer at different times, review strengths and limitations of different assay types and study designs, and discuss methods for rapid sharing and analysis of serologic data to determine global transmission of severe acute respiratory syndrome coronavirus 2. specialized 050EPID 052MALTRA01 26 9 1978-1986 2020 1080-6059 https://www.documentation.ird.fr/hor/fdi:010078775 10.3201/eid2609.201840 1080-6059 [F B010078775] https://www.documentation.ird.fr/hor/fdi:010078775 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers20-09/010078775.pdf IRD - Base Horizon / Pleins textes 2020-09-28 2025-02-24 fdi:010078775 fre